Conatumumab

Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5, TNFRSF10B) with potential antineoplastic activity.^[1][2] Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.^[3][4]

Conatumumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	TRAIL-R2 (CD262)
Clinical data
Other names	anti-TRAIL receptor 2 monoclonal antibody, AMG-655
ATC code	none
Identifiers
CAS Number	896731-82-1 N
ChemSpider	none
UNII	1P48L61KM0
KEGG	D09329 Y
Chemical and physical data
Formula	C6466H10006N1730O2024S40
Molar mass	145645.66 g·mol−1
NY (what is this?)  (verify)

The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.